-
公开(公告)号：EP1132098A4
公开(公告)日：2002-07-31
申请号：EP00961050
申请日：2000-09-18
发明人： MORISHITA RYUICHI , OGIHARA TOSHIO
CPC分类号： A61K38/1833 , A61K38/1866 , A61K48/00
摘要： Cerebrovascular disorders (cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, cerebral attack, cerebral hemorrhage, Willis' circle occlusion, cerebrovascular dementia, Alzheimer's dementia, etc.) can be efficaciously treated or prevented by transferring an HGF (hepatocyte growth factor) gene and/or a VEGF (vascular endothelial growth factor) gene into the subarachnoidal space of humans.
-
公开(公告)号：EP1132098A1
公开(公告)日：2001-09-12
申请号：EP00961050.2
申请日：2000-09-18
CPC分类号： A61K38/1833 , A61K38/1866 , A61K48/00
摘要： By introducing hepatocyte growth factor (HGF) gene and/or vascular endothelial growth factor (VEGF) gene into the subarachnoid space in humans, cerebrovascular disorders such as cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, stroke, cerebral bleeding, moyamoya disease, cerebrovascular dementia, and Alzheimer's dementia can be effectively treated or prevented.
摘要翻译： 通过将肝细胞生长因子（HGF）基因和/或血管内皮生长因子（VEGF）基因引入人类的蛛网膜下腔内，脑血管障碍如脑血管梗阻，脑梗死，脑血栓形成，脑栓塞，中风，脑出血，moyamoya病 ，脑血管性痴呆和阿尔茨海默氏痴呆症可以有效地治疗或预防。
-
公开(公告)号：EP1300158A1
公开(公告)日：2003-04-09
申请号：EP01943840.7
申请日：2001-06-27
IPC分类号： A61K45/00 , A61K48/00 , A61K31/711 , A61K38/18 , A61K31/5585 , A61P9/00 , A61P9/10
CPC分类号： A61K38/52 , A61K31/5585 , A61K31/711 , A61K38/1709 , A61K38/1833 , A61K38/1858 , A61K48/00 , A61K2300/00
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.
摘要翻译： 本发明提供：（1）血管生成治疗用药物组合物，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分，以及生成它们的物质; 和编码血管生成因子的基因; （2）用于增强编码血管生成因子的基因的血管生成作用的药剂，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分; （3）含有前列环素合酶基因作为活性成分的血管生成剂; （4）含有ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; （4）含有ets-1基因作为增强编码血管生成因子的另一基因的血管生成作用的活性成分的药剂; 和（5）含有ets-1基因作为活性成分的血管发生剂。
-
公开(公告)号：EP1142590A1
公开(公告)日：2001-10-10
申请号：EP00971697.8
申请日：2000-10-26
CPC分类号： A61K38/1833 , A61K9/127 , A61K9/1272 , A61K48/00 , A61K48/0016 , A61K48/0025 , A61K48/0075 , C07K14/4753 , C12N7/00 , C12N2760/18843
摘要： It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic site.
摘要翻译： 通过向糖尿病缺血部位施用HGF（肝细胞生长因子）基因，可以刺激由糖尿病下降的缺血部位的血管生成和恢复缺血性疾病。
-
公开(公告)号：EP1136083A1
公开(公告)日：2001-09-26
申请号：EP00964686.0
申请日：2000-10-05
CPC分类号： A61K48/005 , A61K9/127 , A61K38/1833 , A61K48/00 , A61K48/0083
摘要： This invention enables the repair of cardiac function by noninvasive administration of an HGF gene in the form of Sendai virus (HVJ)-liposome into the affected cardiac muscle, thereby inducing angiogenesis of the cardiac muscle layer and repressing fibrosis.
摘要翻译： 本发明能够通过非侵入性地将仙台病毒（HVJ） - 脂质体形式的HGF基因侵入受影响的心肌来修复心脏功能，从而诱导心肌层的血管生成并抑制纤维化。
-
-
-
-
搜索结果
5 条记录 (耗时 0.011 秒)
